Complete lymph node dissection for sentinel node-positive melanoma: Assessment of practice patterns in the United States

Annals of Surgical Oncology

Volumn 15, Issue 6, 2008, Pages 1566-1576

  Bilimoria, Karl Y ^a,b   Balch, Charles M ^c   Bentrem, David J ^b   Talamonti, Mark S ^b,d   Ko, Clifford Y ^a,e,f   Lange, Julie R ^c   Winchester, David P ^a,b,d   Wayne, Jeffrey D ^b  

^a American College of Surge   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Evanston Northwestern Healthcare ^*  (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Completion lymph node dissection; Lymph node; Melanoma; Sentinel lymph node biopsy; Skin neoplasm; Surgery

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; SENTINEL LYMPH NODE;

AGED; CLINICAL COMPETENCE; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROFESSIONAL PRACTICE; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; UNITED STATES;

EID: 43449103331     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9885-2     Document Type: Article

References (47)

1. Desmond RA, Soong SJ. Epidemiology of malignant melanoma. Surg Clin North Am 2003; 83:1-29.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007; 57:43-66
3. Horm JW, Sondik EJ. Person-years of life lost due to cancer in the United States, 1970 and 1984. Am J Public Health 1989; 79:1490-3
4. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-83
5. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-9
6. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7:87-97
7. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-17
8. Morton DL, Scheri RP, Balch CM. Can completion lymph node dissection be avoided for a positive sentinel node in melanoma? Ann Surg Oncol 2007; 14:2437-9
9. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006; 13:809-16
10. Complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis who have undergone sentinel lymphadenectomy (MSLT-II). Available at: http://www.clinicaltrials.gov/ct/show/ NCT00389571?order=1. Accessed March 14, 2008
11. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: melanoma. v.2.2007. Available at: http://www.nccn.org/. Accessed March 14, 2008
12. Bilimoria KY, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008; 15:683-90
13. Winchester DP, Stewart AK, Bura C, et al. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol 2004; 85:1-3
14. World Health Organization. International Classification of Disease for Oncology. 3rd ed. Geneva: World Health Organization, 2000
15. Department of Health, Human Services. The International Classification of Diseases. 9th revised. clinical modification: ICD-9-CM. Washington, DC: Government Printing Office, 1998
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9
18. United States Census Bureau. Census 2000. http://www.census.gov/main/www/ cen2000.html. Accessed March 14, 2008
19. Facility Oncology Registry Data Standards. Chicago: Commission on Cancer, 2004
20. AJCC Cancer Staging Manual, 6th ed. Chicago IL: Springer, 2002
21. Panageas KS, Schrag D, Riedel E, et al. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med 2003; 139:658-65
22. Hosmer J, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1999
23. Cormier JN, Xing Y, Ding M, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol 2005; 23:6054-62
24. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006; 13:302-9
25. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005; 201:37-47
26. Scheri RP, Essner R, Turner RR, et al. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 2007; 14:2861-6
27. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004; 22:3677-84
28. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003; 10:676-80
29. Baas PC, Schraffordt Koops H, Hoekstra HJ, et al. Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. Arch Surg 1992; 127:281-6
30. Bland KI, Klamer TW, Polk HC Jr, et al. Isolated regional lymph node dissection: morbidity, mortality and economic considerations. Ann Surg 1981; 193:372-6
31. Hughes TM, Thomas JM. Combined inguinal and pelvic lymph node dissection for stage III melanoma. Br J Surg 1999; 86:1493-8
32. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006; 24:4464-71
33. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370-80
34. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17
35. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004; 11(3 Suppl):162S-8S
36. Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999; 134:43-9
37. Malin JL, Kahn KL, Adams J, et al. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 2002; 94:835-44
38. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999; 86:617-27
39. Stojadinovic A, Allen PJ, Clary BM, et al. Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg 2002; 235:92-8
40. Tanis PJ, Boom RP, Koops HS, et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 2001; 8:222-6
41. Galliot-Repkat C, Cailliod R, Trost O, et al. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Eur J Surg Oncol 2006; 32:790-4
42. Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study. Ann Surg Oncol 2005; 12:981-7
43. Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005; 97:219-25
44. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 2006; 13:1189-200
45. Bilimoria KY, Palis BE, Stewart AK, et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum 2008; 51:154-61
46. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Impact of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg (in press)
47. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348:2635-45